Rationale and design of phase II clinical trial of dual inhibition with ramucirumab and erlotinib in EGFR exon 19 deletion-positive treatment-naïve non-small cell lung cancer with...

por Kawachi, Hayato, Yamada, Tadaaki, Yoshimura, Akihiro, Morimoto, Kenji, Iwasaku, Masahiro, Tokuda, Shinsaku, Kim, Young Hak, Shimose, Takayuki, Takayama, Koichi
Publicado 2023

Switching from first or second generation EGFR-TKI to osimertinib in EGFR mutation-positive NSCLC

por Imamura, Fumio, Inoue, Takako, Kunimasa, Kei, Kubota, Aki, Kuhara, Hanako, Tamiya, Motohiro, Nishino, Kazumi, Kimura, Madoka, Kuno, Kika, Kawachi, Hayato, Kumagai, Toru
Publicado 2020

Impact of docetaxel plus ramucirumab on metastatic site in previously treated patients with non-small cell lung cancer: a multicenter retrospective study

por Matsumoto, Kinnosuke, Tamiya, Akihiro, Matsuda, Yoshinobu, Taniguchi, Yoshihiko, Atagi, Shinji, Kawachi, Hayato, Tamiya, Motohiro, Tanizaki, Satoshi, Uchida, Junji, Ueno, Kiyonobu, Yanase, Takafumi, Suzuki, Hidekazu, Hirashima, Tomonori
Publicado 2021

Efficacy of Immune Checkpoint Inhibitor With or Without Chemotherapy for Nonsquamous NSCLC With Malignant Pleural Effusion: A Retrospective Multicenter Cohort Study

por Kawachi, Hayato, Tamiya, Motohiro, Taniguchi, Yoshihiko, Yokoyama, Toshihide, Yokoe, Shinya, Oya, Yuko, Imaji, Mihoko, Okabe, Fukuko, Kanazu, Masaki, Sakata, Yoshihiko, Uematsu, Shinya, Tanaka, Satoshi, Arai, Daisuke, Saito, Go, Kobe, Hiroshi, Miyauchi, Eisaku, Okada, Asuka, Hara, Satoshi, Kumagai, Toru
Publicado 2022

First-Line Chemoimmunotherapy versus Sequential Platinum-Based Chemotherapy Followed by Immunotherapy in Patients with Non-Small Cell Lung Cancer with ≤49% Programmed Death-Ligand...

por Tanimura, Keiko, Takeda, Takayuki, Kataoka, Nobutaka, Yoshimura, Akihiro, Nakanishi, Kentaro, Yamanaka, Yuta, Yoshioka, Hiroshige, Honda, Ryoichi, Uryu, Kiyoaki, Fukui, Mototaka, Chihara, Yusuke, Takei, Shota, Kawachi, Hayato, Yamada, Tadaaki, Tamiya, Nobuyo, Okura, Naoko, Yamada, Takahiro, Murai, Junji, Shiotsu, Shinsuke, Kurata, Takayasu, Takayama, Koichi
Publicado 2023

Concomitant Proton Pump Inhibitor Use With Pembrolizumab Monotherapy vs Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With Non−Small Cell Lung Cancer

por Kawachi, Hayato, Yamada, Tadaaki, Tamiya, Motohiro, Negi, Yoshiki, Goto, Yasuhiro, Nakao, Akira, Shiotsu, Shinsuke, Tanimura, Keiko, Takeda, Takayuki, Okada, Asuka, Harada, Taishi, Date, Koji, Chihara, Yusuke, Hasegawa, Isao, Tamiya, Nobuyo, Ishida, Masaki, Katayama, Yuki, Morimoto, Kenji, Iwasaku, Masahiro, Tokuda, Shinsaku, Kijima, Takashi, Takayama, Koichi
Publicado 2023

Adaptive resistance to lorlatinib via EGFR signaling in ALK-rearranged lung cancer

por Katayama, Yuki, Yamada, Tadaaki, Tanimura, Keiko, Tokuda, Shinsaku, Morimoto, Kenji, Hirai, Soichi, Matsui, Yohei, Nakamura, Ryota, Ishida, Masaki, Kawachi, Hayato, Yoneda, Kazue, Hosoya, Kazutaka, Tsuji, Takahiro, Ozasa, Hiroaki, Yoshimura, Akihiro, Iwasaku, Masahiro, Kim, Young Hak, Horinaka, Mano, Sakai, Toshiyuki, Utsumi, Takahiro, Shiotsu, Shinsuke, Takeda, Takayuki, Katayama, Ryohei, Takayama, Koichi
Publicado 2023